

# Activation and Regulation of T Lymphocytes

Abul K. Abbas  
UCSF

**FOCiS**

**UCSF**

University of California  
San Francisco


*advancing health worldwide™*




## Lecture outline

- T cell activation
- Costimulation, the B7:CD28 family
- Regulation by coinhibitors: CTLA-4, PD-1


# Molecules involved in T cell activation



# TCR signal transduction



# The two-signal requirement for lymphocyte activation




# Role of costimulation in T cell activation

Antigen recognition

T cell response

"Resting"  
(costimulator-deficient) APC




Naive T cell

No response or tolerance


Activation of APCs by microbes, innate immune response

Activated APC: increased expression of costimulators, secretion of cytokines



Cytokines (e.g., IL-12)

Effector and memory T cells





T cell proliferation and differentiation

# Costimulation

- Required for initiating T cell responses (activation of naïve T cells)
- Ensures that T cells respond to microbes (the best inducers of costimulators) and not to harmless antigens
  - Source of costimulation during responses to tumors, transplants?


# Costimulatory blockade



CTLA4-Ig (abatacept/belatacept) is approved for rheumatoid arthritis, graft rejection



# The B7:CD28 families



# Inhibitory receptors of T cells

- Prevent reactions against self antigens
- Limit immune responses in situations of persistent stimulation: some tumors, chronic infections
  - Therapeutic application: checkpoint blockade for cancer immunotherapy


# Opposing functions of CD28 and CTLA-4

- CD28 on T cells recognizes B7 on APCs  
→ T cell activation
- CTLA-4 recognizes B7 → inhibition of T cells
  - Knockout of CTLA-4 in mice or mutations in humans results in systemic inflammatory disease

## The PD-1 inhibitory pathway


- PD-1 recognizes two widely expressed ligands (PD-L1, PD-L2)
- Knockout of PD-1 leads to autoimmune disease (less severe than CTLA-4-KO)
- Role of PD-1 in T cell suppression in chronic infections, tumors?

# T cell activation




# Action of PD-1

TCR stimulation      PD-1 engagement      CD28 costimulation




**PD-1 inhibits signals from the TCR complex and CD28**

# CTLA-4 on Tregs inhibits responding T cells



*Tregs are the only cells that constitutively express high levels of CTLA-4 (transient expression on recently activated conventional T cells)*  
*Deletion of CTLA-4 in Tregs recapitulates germline deletion*


# B7 engages CD28 in the absence of CTLA-4






# CTLA-4 blocks and removes B7

No CTLA-4 expressed



CTLA-4 expressed




*CTLA-4 has ~20-fold higher affinity for B7 than CD28: out-competes CD28*

# Functions of CTLA-4

- **Limits activation of responding T cells**
- How does the T cell choose to use CD28 to be activated (e.g., with microbes) or CTLA-4 to shut down (e.g., with self Ag)?
  - Level of B7 expression and affinity of receptors: Low B7 (e.g., when DC is displaying self or tumor antigen) --> engagement of high-affinity CTLA-4
  - High B7 (e.g., after microbe encounter) --> engagement of lower affinity CD28


# Consequence of mutations in the CTLA-4 pathway



Unopposed costimulation →  
Excessive T cell activation

Therapy?


# Chronic infections induce T cell exhaustion



# T cell activating and inhibitory receptors

Inhibitory receptors  
(coinhibitors)

Activating receptors  
(costimulators)



## Costimulators and inhibitors other than the B7:CD28 family

- Many proteins of the TNF-receptor and Ig families are expressed on T cells and implicated in T-cell activation and control
  - Functions often demonstrated in complex experimental systems or in vitro
  - Often expressed on both effector and regulatory T cells, so functions unclear
  - Roles in disease (human or animal models) not definitely established
- Possible therapeutic targets?